Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.40 -2.8%	$1.32	$1.05 ▼ $5.17	$159.17M	0.41	1.19 million shs	522,832 shs
ENTA Enanta Pharmaceuticals	$7.05 -3.2%	$5.91	$4.09 ▼ $17.24	$160.32M	0.76	285,339 shs	123,925 shs
SEOVF Sernova Biotherapeutics	$0.12 +1.2%	$0.14	$0.10 ▼ $0.29	$41.32M	1.08	36,515 shs	2,589 shs
SLN Silence Therapeutics	$5.37 +6.1%	$4.25	$1.97 ▼ $22.47	N/A	1.41	303,802 shs	97,104 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-2.78%	-7.28%	+6.87%	-9.68%	+23.89%
ENTA Enanta Pharmaceuticals	-3.16%	-6.99%	+22.61%	+9.47%	-41.59%
SEOVF Sernova Biotherapeutics	+1.16%	-0.25%	-18.73%	-2.32%	-46.56%
SLN Silence Therapeutics	+6.13%	+4.27%	+22.88%	+42.06%	-71.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4739 of 5 stars	3.6	1.0	0.0	0.0	2.4	1.7	1.3
ENTA Enanta Pharmaceuticals	3.7307 of 5 stars	3.4	1.0	0.0	4.7	2.0	2.5	0.0
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	2.6806 of 5 stars	3.4	4.0	0.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	593.88% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	155.32% Upside
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	530.04% Upside

Current Analyst Ratings Breakdown

Latest SEOVF, ENTA, SLN, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/18/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	8.10	N/A	N/A	$1.44 per share	0.97
ENTA Enanta Pharmaceuticals	$67.64M	2.23	N/A	N/A	$6.08 per share	1.16
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
SEOVF Sernova Biotherapeutics	-$23.65M	-$0.04	N/A	∞	N/A	N/A	N/A	-358.68%	N/A
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/15/2025 (Estimated)

Latest SEOVF, ENTA, SLN, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q2 2025	SEOVF Sernova Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
SEOVF Sernova Biotherapeutics	N/A	0.10	0.10
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ENTA Enanta Pharmaceuticals	94.99%
SEOVF Sernova Biotherapeutics	N/A
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
ENTA Enanta Pharmaceuticals	13.89%
SEOVF Sernova Biotherapeutics	N/A
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
SEOVF Sernova Biotherapeutics	N/A	328.48 million	N/A	Not Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

SEOVF, ENTA, SLN, and ACRS Headlines

Recent News About These Companies

Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"

June 16 at 1:31 AM | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan Capital

June 16 at 1:31 AM | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC Wainwright

June 15 at 1:45 AM | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street Zen

June 14, 2025 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)

June 13, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan Capital

June 13, 2025 | marketbeat.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83

June 10, 2025 | americanbankingnews.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Analysts

June 7, 2025 | marketbeat.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
By Gabriel Osorio-Mazilli | June 6, 2025
View A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
By Jeffrey Neal Johnson | June 10, 2025
View ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
Is NIO Stock Set for a Comeback? Fundamentals Say Yes
By Gabriel Osorio-Mazilli | May 19, 2025
View Is NIO Stock Set for a Comeback? Fundamentals Say Yes
Ignore the Noise—Samsara Stock Is Still a Strong Buy
By Sam Quirke | June 12, 2025
View Ignore the Noise—Samsara Stock Is Still a Strong Buy
Why Analysts Are Bullish on Celsius Stock After 30% Drop
By Gabriel Osorio-Mazilli | June 16, 2025
View Why Analysts Are Bullish on Celsius Stock After 30% Drop

SEOVF, ENTA, SLN, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.40 -0.04 (-2.78%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$1.45 +0.05 (+3.57%)

As of 06/17/2025 07:56 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.05 -0.23 (-3.16%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$7.06 +0.01 (+0.14%)

As of 06/17/2025 04:04 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.12 +0.00 (+1.16%)

As of 06/17/2025 11:18 AM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Silence Therapeutics NASDAQ:SLN

$5.37 +0.31 (+6.13%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$5.38 +0.01 (+0.28%)

As of 06/17/2025 04:04 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time